Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 15–25 % weight loss over 12–24 months, but questions remain about the potential influence of concomitant losses in muscle mass. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.